ENVISAGENICS INC

Long Island City, NY · Founded 2014 · Biotech · Private

SpliceIO, a software platform for cancer neoantigen discovery from RNA sequencing data by identifying splicing errors

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · envisagenics.com

Sector: Biotech
Headquarters: Long Island City, NY
Founded: 2014
Latest Form D: $19.2M, Oct 2021
Total capital: $27.6M

Federal grants: $8.5M; 12 awards · 2015–2023; Rank in peer group#8 of 19
Private capital raised: $19.2M; 2 Form D · last Oct 2021; 60 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 11 pending

Capital timeline

Latest events

Jul 2023Federal grantHealth and Human S · Phase II · Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data$77K
May 2023Federal grantHealth and Human S · Phase II · Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data$980K
Jul 2022Federal grantHealth and Human S · Phase II · Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data$2.1M
Jun 2022Federal grantHealth and Human S · Phase II · Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data$1M
Oct 2021Private capital raisedForm D · SEC · 2nd filing$19.2M
Sep 2019Federal grantHealth and Human S · Phase I · A Software Platform for the Identification of Cell Surface Antigens Using RNA-seq Data$302K
Sep 2019Federal grantHealth and Human S · Phase I · A Software Platform for the Identification of Cell Surface Antigens Using RNA-seq Data$302K
Mar 2017Offering registeredForm D · SEC · 1st filing$2M

Show 6 earlier federal awards

Mar 2019Federal grantHealth and Human S · Phase II · SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data$517K
Aug 2018Federal grantHealth and Human S · Phase II · SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data$125K
Apr 2018Federal grantHealth and Human S · Phase II · SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data$1.6M
Apr 2018Federal grantHealth and Human S · Phase II · SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data$983K
Aug 2015Federal grantHealth and Human S · Phase I · SpliceCore: A cloud-based platform to detect, quantify and interpret alternative splicing variation from next-generation sequencing data.$225K
Aug 2015Federal grantHealth and Human S · Phase I · SpliceCore: A cloud-based platform to detect, quantify and interpret alternative splicing variation from next-generation sequencing data.$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

19months

from ENVISAGENICS INC’s first federal award to its first private round.

First federal award · Aug 2015: Health and Human S · $225K
First Form D · Mar 2017: $2M · 1st Form D
Awards before first raise: 2 awards

An association in public records, not a cause or a prediction.

Standing among 19 peers

Line = median

Biotech · Software

Federal grants#8 · top 42%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Martin Luisa AkermanResearcherExecutive Officer, Director, PromoterLinked by $8.5M in grants as PI
ALAN S. ROEMERDirectorNamed in SEC Form D filings
BRADLEY S. HARRISExecutive OfficerNamed in SEC Form D filings
GRANT LUISA VERSTANDINGDirectorNamed in SEC Form D filings
Maria Luisa PinedaExecutive Officer, Director, PromoterNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 11

Aug 24, 2023PendingNeoantigens, Methods And Detection Of Use ThereofUSPTOApplication 18023674
Apr 14, 2022PendingCancer-specific Molecules And Methods Of Use ThereofUSPTOApplication 17495266
Sep 9, 2021PendingSystems And Methods For Analysis Of Alternative SplicingUSPTOApplication 16952231

Show all 11 patent records

Neoantigens, Methods And Detection Of Use ThereofAug 24, 2023 · Application 18023674Pending
Cancer-specific Molecules And Methods Of Use ThereofApr 14, 2022 · Application 17495266Pending
Systems And Methods For Analysis Of Alternative SplicingSep 9, 2021 · Application 16952231Pending
Cancer-specific Molecules And Methods Of Use ThereofApplication PCTUS2020027534Pending
Cancer-specific Oligonucleotides And Methods Of Use ThereofApplication 62980900Pending
Novel Splice Variants in Triple Negative Breast CancerApplication 62944913Pending
Systems And Methods For Analysis Of Alternative SplicingApplication PCTUS2019033574Pending
Breast Cancer-specific Oligonucleotides And Methods Of Use ThereofApplication 62831604Pending
Systems And Methods For Analysis Of Alternative SplicingApplication 62675590Pending
Neoantigens, Methods And Detection Of Use ThereofApplication PCTUS2021048073Pending
Neoantigens, Methods Of Detection And Use ThereofApplication 63071516Pending

Paragon Bioservices, Inc.Similar federal contract value in Biotech · null in contracts
BASEPAIR, INC.Similar federal contract value in Biotech · null in contracts
ADVANTAGE THERAPEUTICS, INCSimilar federal contract value in Biotech · null in contracts
Quralis CorporationSimilar federal contract value in Biotech · null in contracts
Scribe Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
GENEVENTIV THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.